<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:12:10Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9558428" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9558428</identifier>
        <datestamp>2022-10-14</datestamp>
        <setSpec>erjopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Eur Respir J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur Respir J</journal-id>
              <journal-id journal-id-type="publisher-id">ERJ</journal-id>
              <journal-id journal-id-type="hwp">erj</journal-id>
              <journal-title-group>
                <journal-title>The European Respiratory Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0903-1936</issn>
              <issn pub-type="epub">1399-3003</issn>
              <publisher>
                <publisher-name>European Respiratory Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9558428</article-id>
              <article-id pub-id-type="pmcid">PMC9558428</article-id>
              <article-id pub-id-type="pmc-uid">9558428</article-id>
              <article-id pub-id-type="pmid">36229048</article-id>
              <article-id pub-id-type="pmid">36229048</article-id>
              <article-id pub-id-type="doi">10.1183/13993003.01870-2021</article-id>
              <article-id pub-id-type="publisher-id">ERJ-01870-2021</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research Articles</subject>
                  <subj-group>
                    <subject>Covid-19</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>4</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)</article-title>
                <alt-title alt-title-type="short">Anti-GM-CSF otilimab in severe COVID-19 pneumonia</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Jatin</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bass</surname>
                    <given-names>Damon</given-names>
                  </name>
                  <xref rid="af2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Beishuizen</surname>
                    <given-names>Albertus</given-names>
                  </name>
                  <xref rid="af3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bocca Ruiz</surname>
                    <given-names>Xavier</given-names>
                  </name>
                  <xref rid="af4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boughanmi</surname>
                    <given-names>Hatem</given-names>
                  </name>
                  <xref rid="af5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cahn</surname>
                    <given-names>Anthony</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Colombo</surname>
                    <given-names>Hugo</given-names>
                  </name>
                  <xref rid="af6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Criner</surname>
                    <given-names>Gerard J.</given-names>
                  </name>
                  <xref rid="af7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davy</surname>
                    <given-names>Katherine</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de-Miguel-Díez</surname>
                    <given-names>Javier</given-names>
                  </name>
                  <xref rid="af8" ref-type="aff">8</xref>
                  <xref rid="af9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Doreski</surname>
                    <given-names>Pablo A.</given-names>
                  </name>
                  <xref rid="af10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fernandes</surname>
                    <given-names>Sofia</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>François</surname>
                    <given-names>Bruno</given-names>
                  </name>
                  <xref rid="af11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Anubha</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9629-8491</contrib-id>
                  <name>
                    <surname>Hanrott</surname>
                    <given-names>Kate</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hatlen</surname>
                    <given-names>Timothy</given-names>
                  </name>
                  <xref rid="af12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Inman</surname>
                    <given-names>Dave</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Isaacs</surname>
                    <given-names>John D.</given-names>
                  </name>
                  <xref rid="af13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jarvis</surname>
                    <given-names>Emily</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5128-5005</contrib-id>
                  <name>
                    <surname>Kostina</surname>
                    <given-names>Natalia</given-names>
                  </name>
                  <xref rid="af14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kropotina</surname>
                    <given-names>Tatiana</given-names>
                  </name>
                  <xref rid="af15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lacherade</surname>
                    <given-names>Jean-Claude</given-names>
                  </name>
                  <xref rid="af16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lakshminarayanan</surname>
                    <given-names>Divya</given-names>
                  </name>
                  <xref rid="af17" ref-type="aff">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Martinez-Ayala</surname>
                    <given-names>Pedro</given-names>
                  </name>
                  <xref rid="af18" ref-type="aff">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McEvoy</surname>
                    <given-names>Charlene</given-names>
                  </name>
                  <xref rid="af19" ref-type="aff">19</xref>
                  <xref rid="af20" ref-type="aff">20</xref>
                  <xref rid="af21" ref-type="aff">21</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meziani</surname>
                    <given-names>Ferhat</given-names>
                  </name>
                  <xref rid="af22" ref-type="aff">22</xref>
                  <xref rid="af23" ref-type="aff">23</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Monchi</surname>
                    <given-names>Mehran</given-names>
                  </name>
                  <xref rid="af24" ref-type="aff">24</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mukherjee</surname>
                    <given-names>Sumanta</given-names>
                  </name>
                  <xref rid="af17" ref-type="aff">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Muñoz-Bermúdez</surname>
                    <given-names>Rosana</given-names>
                  </name>
                  <xref rid="af25" ref-type="aff">25</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neisen</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O'Shea</surname>
                    <given-names>Ciara</given-names>
                  </name>
                  <xref rid="af26" ref-type="aff">26</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3070-7368</contrib-id>
                  <name>
                    <surname>Plantefeve</surname>
                    <given-names>Gaëtan</given-names>
                  </name>
                  <xref rid="af27" ref-type="aff">27</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schifano</surname>
                    <given-names>Lorrie</given-names>
                  </name>
                  <xref rid="af2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schwab</surname>
                    <given-names>Lee E.</given-names>
                  </name>
                  <xref rid="af28" ref-type="aff">28</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shahid</surname>
                    <given-names>Zainab</given-names>
                  </name>
                  <xref rid="af29" ref-type="aff">29</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shirano</surname>
                    <given-names>Michinori</given-names>
                  </name>
                  <xref rid="af30" ref-type="aff">30</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Julia E.</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sprinz</surname>
                    <given-names>Eduardo</given-names>
                  </name>
                  <xref rid="af31" ref-type="aff">31</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7269-2873</contrib-id>
                  <name>
                    <surname>Summers</surname>
                    <given-names>Charlotte</given-names>
                  </name>
                  <xref rid="af32" ref-type="aff">32</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4036-6245</contrib-id>
                  <name>
                    <surname>Terzi</surname>
                    <given-names>Nicolas</given-names>
                  </name>
                  <xref rid="af33" ref-type="aff">33</xref>
                  <xref rid="af34" ref-type="aff">34</xref>
                  <xref rid="af35" ref-type="aff">35</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tidswell</surname>
                    <given-names>Mark A.</given-names>
                  </name>
                  <xref rid="af36" ref-type="aff">36</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trefilova</surname>
                    <given-names>Yuliya</given-names>
                  </name>
                  <xref rid="af37" ref-type="aff">37</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williamson</surname>
                    <given-names>Russell</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wyncoll</surname>
                    <given-names>Duncan</given-names>
                  </name>
                  <xref rid="af38" ref-type="aff">38</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Layton</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref rid="af1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="af1"><label>1</label>GSK Medicines Research Centre, Stevenage, UK</aff>
              <aff id="af2"><label>2</label>GSK, Research Triangle Park, NC, USA</aff>
              <aff id="af3"><label>3</label>Intensive Care Center, Medisch Spectrum Twente, Enschede, The Netherlands</aff>
              <aff id="af4"><label>4</label>Servicio de Neumonologia, Clinica Monte Grande, Buenos Aires, Argentina</aff>
              <aff id="af5"><label>5</label>Service de Réanimation, CH Valenciennes - Hôpital Jean Bernard, Valenciennes Cedex, France</aff>
              <aff id="af6"><label>6</label>Clinica Privada Colombo, Córdoba, Argentina</aff>
              <aff id="af7"><label>7</label>Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA, USA</aff>
              <aff id="af8"><label>8</label>Respiratory Dept, Hospital General Universitario Gregorio Marañón, Madrid, Spain</aff>
              <aff id="af9"><label>9</label>Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain</aff>
              <aff id="af10"><label>10</label>Clinica Independencia de Munro, Buenos Aires, Argentina</aff>
              <aff id="af11"><label>11</label>Service Réanimation Polyvalente and Inserm CIC1435 &amp; UMR1092, CHU Limoges, Limoges Cedex, France</aff>
              <aff id="af12"><label>12</label>Harbor-UCLA Medical Center, Torrance, CA, USA</aff>
              <aff id="af13"><label>13</label>Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK</aff>
              <aff id="af14"><label>14</label>Voronezh Regional Clinical Hospital, Voronezh, Russia</aff>
              <aff id="af15"><label>15</label>BUZ Regional Clinical Hospital, Omsk, Russia</aff>
              <aff id="af16"><label>16</label>Service de Médecine Intensive Réanimation, CHD Vendée - Site De La Roche-sur-Yon, La Roche-Sur-Yon, France</aff>
              <aff id="af17"><label>17</label>GSK, Collegeville, PA, USA</aff>
              <aff id="af18"><label>18</label>Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico</aff>
              <aff id="af19"><label>19</label>Regions Hospital, St. Paul, MN, USA</aff>
              <aff id="af20"><label>20</label>Methodist Hospital, St. Louis Park, MN, USA</aff>
              <aff id="af21"><label>21</label>HealthPartners Institute, Bloomington, MN, USA</aff>
              <aff id="af22"><label>22</label>Dept of Intensive Care, Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpital Universitaire de Strasbourg, Strasbourg, France</aff>
              <aff id="af23"><label>23</label>CRICS-TRIGGERSEP F-CRIN Network, Strasbourg, France</aff>
              <aff id="af24"><label>24</label>Groupe Hospitalier Sud Ile-de-France, Melun, France</aff>
              <aff id="af25"><label>25</label>Hospital del Mar-IMIM, Barcelona, Spain</aff>
              <aff id="af26"><label>26</label>GSK, Dublin, Ireland</aff>
              <aff id="af27"><label>27</label>Service de Réanimation Polyvalente, CH Victor Dupouy, Argenteuil, France</aff>
              <aff id="af28"><label>28</label>Holy Cross Health, Silver Spring, MD, USA</aff>
              <aff id="af29"><label>29</label>Levine Cancer Institute, Atrium Health, Charlotte, NC, USA</aff>
              <aff id="af30"><label>30</label>Osaka City General Hospital, Osaka, Japan</aff>
              <aff id="af31"><label>31</label>Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil</aff>
              <aff id="af32"><label>32</label>Dept of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK</aff>
              <aff id="af33"><label>33</label>Médecine Intensive Réanimation, CHU Grenoble-Alpes, Grenoble, France</aff>
              <aff id="af34"><label>34</label>Université Grenoble-Alpes, Grenoble, France</aff>
              <aff id="af35"><label>35</label>INSERM U1042, Grenoble, France</aff>
              <aff id="af36"><label>36</label>Pulmonary and Critical Care, Baystate Medical Centre, Springfield, MA, USA</aff>
              <aff id="af37"><label>37</label>Perm Regional Clinical Hospital, Perm, Russia</aff>
              <aff id="af38"><label>38</label>Dept of Critical Care, Guy's and St Thomas’ NHS Foundation Trust, London, UK</aff>
              <author-notes>
                <corresp id="cor1">Corresponding author: Anthony Cahn (<email xlink:href="tony.x.cahn@gsk.com">tony.x.cahn@gsk.com</email>)</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>02</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <volume>61</volume>
              <issue>2</issue>
              <elocation-id>2101870</elocation-id>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright ©The authors 2023.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact <ext-link ext-link-type="uri" xlink:href="mailto:permissions@ersnet.org">permissions@ersnet.org</ext-link></license-p>
                </license>
              </permissions>
              <related-article related-article-type="commentary" ext-link-type="doi" id="RA1" xlink:href="10.1183/13993003.02091-2022"/>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 <italic toggle="yes">versus</italic> 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI −0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI −9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short">
                <p>
                  <bold>Therapeutic blocking of GM-CSF with otilimab did not significantly improve clinical status in patients with severe COVID-19; however, otilimab demonstrated an acceptable safety profile and reduced markers of inflammation</bold>
                  <ext-link xlink:href="https://bit.ly/3QquyYP" ext-link-type="uri">https://bit.ly/3QquyYP</ext-link>
                </p>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>GlaxoSmithKline</institution>
                      <institution-id institution-id-type="doi">10.13039/100004330</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Severe COVID-19 is characterised by respiratory and/or multi-organ failure [<xref rid="C1" ref-type="bibr">1</xref>]. A subset of patients displays systemic hyperinflammation including dysregulated myeloid cell responses [<xref rid="C2" ref-type="bibr">2</xref>–<xref rid="C4" ref-type="bibr">4</xref>]. Older age and associated immunosenescence and underlying comorbidities may predispose patients to similar immune abnormalities to those observed in COVID-19 [<xref rid="C5" ref-type="bibr">5</xref>, <xref rid="C6" ref-type="bibr">6</xref>], increasing their risk of severe disease and mortality [<xref rid="C7" ref-type="bibr">7</xref>–<xref rid="C9" ref-type="bibr">9</xref>].</p>
              <p>Granulocyte–macrophage colony-stimulating factor (GM-CSF) is implicated in driving hyperinflammation in severe COVID-19 [<xref rid="C10" ref-type="bibr">10</xref>–<xref rid="C14" ref-type="bibr">14</xref>], with increased circulating concentrations reportedly associated with COVID-19 severity and mortality [<xref rid="C12" ref-type="bibr">12</xref>, <xref rid="C15" ref-type="bibr">15</xref>]. This may be due to the putative role of GM-CSF in myeloid cell activation, differentiation, survival and priming to enhance inflammatory cytokine and chemokine production, leading to further myeloid cell recruitment to sites of inflammation. This potentially produces a positive feedback loop driving cytokine and chemokine production, hyperinflammation and tissue damage [<xref rid="C10" ref-type="bibr">10</xref>, <xref rid="C11" ref-type="bibr">11</xref>].</p>
              <p>Otilimab is a high-affinity, fully human, anti-GM-CSF monoclonal antibody (IgG1λ) that reduces inflammatory activity in rheumatoid arthritis (RA) [<xref rid="C16" ref-type="bibr">16</xref>]. GM-CSF inhibition with otilimab was hypothesised to reduce the production of proinflammatory cytokines and chemokines, decrease myeloid cell migration and modulate hyperinflammation, leading to an improved outcome in severe COVID-19 [<xref rid="C10" ref-type="bibr">10</xref>]. The otilimab in severe COVID-19-related disease (OSCAR) trial was designed to investigate the efficacy and safety of otilimab in patients with acute respiratory failure and systemic inflammation due to severe COVID-19.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2a">
                <title>Study design</title>
                <p>OSCAR was a randomised, multicentre, placebo-controlled, double-blind study (GSK study 214094; NCT04376684) conducted at 121 sites across 19 countries (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>). This sequential study was conducted in two parts: Part 1 enrolled patients aged 18–≤79 years between 28 May 2020 and 15 November 2020, with the last patient completing Day 60 on 13 January 2021. Part 1 results indicated a potential benefit of otilimab in a predefined subgroup of patients aged 70–79 years. Therefore, the original protocol was amended to include Part 2, which enrolled only patients aged ≥70 years between 15 February 2021 and 19 June 2021, with the last patient completing Day 60 on 16 August 2021.</p>
                <p>Patients were randomised 1:1 in a blinded manner, using interactive response technology (block size of four) to receive otilimab or matched placebo. Patients were monitored daily until Day 28 (or until hospital discharge), with follow-up assessments at Days 42 and 60.</p>
                <p>The study was conducted in accordance with the Declaration of Helsinki, Council for International Organisations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation, Good Clinical Practice and applicable country-specific regulatory requirements. The protocol was approved by relevant institutional review boards. Before enrolment, informed consent was obtained from the patient or their legally authorised representative. An independent data monitoring committee monitored in-stream unblinded safety and efficacy data throughout the study.</p>
              </sec>
              <sec id="s2b">
                <title>Patients</title>
                <p>Eligible patients were aged 18–79 years in Part 1 and ≥70 years in Part 2, had a positive SARS-CoV-2 result from any validated test (predominantly reverse transcription PCR) and were hospitalised due to radiographically confirmed pneumonia consistent with COVID-19. All patients had a clinical status of Category 5 or 6 in the modified World Health Organization Ordinal Scale for Clinical Improvement (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary methods</ext-link>) [<xref rid="C17" ref-type="bibr">17</xref>], defined by recent onset of oxygenation impairment requiring either high-flow oxygen (≥15 L·min<sup>−1</sup>; Category 5), noninvasive ventilation (Category 5) or invasive mechanical ventilation without additional organ support (Category 6) ≤48 h prior to dosing. Serum concentrations of the inflammatory markers C-reactive protein (CRP) or ferritin were required to be above the upper limit of normal.</p>
                <p>Patients were excluded if death was predicted within 48 h; if they had multiple organ failure according to the investigator's opinion and/or a Sequential Organ Failure Assessment [<xref rid="C18" ref-type="bibr">18</xref>] score &gt;10; or if they were receiving extracorporeal membrane oxygenation, haemofiltration/dialysis or more than one inotrope or vasopressor of any class. Patients who had received intravenous immunoglobulin, monoclonal antibody or immunosuppressant therapy within the past 3 months or who were currently receiving chronic oral corticosteroids (&gt;10 mg·day<sup>−1</sup> prednisone or equivalent) for a non-COVID-19 indication were also excluded. Full eligibility criteria are provided in the <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>.</p>
              </sec>
              <sec id="s2c">
                <title>Study treatments</title>
                <p>Patients received either a single 1-h intravenous infusion of otilimab 90 mg or placebo on Day 1 and standard of care according to current clinical guidelines and institutional protocols. This otilimab dosing regimen was predicted to result in serum concentrations remaining within the target range for ∼1 week, which was deemed to be sufficient to inhibit the expected levels of GM-CSF in circulation/tissue and induce an anti-inflammatory effect, while allowing a return to normal GM-CSF levels in the recovery phase, during which GM-CSF expression may promote lung repair [<xref rid="C10" ref-type="bibr">10</xref>].</p>
              </sec>
              <sec id="s2d">
                <title>End-points and assessments</title>
                <p>The primary end-point was the proportion of patients alive and free of respiratory failure (clinical status: Categories 1–4) at Day 28. Key secondary end-points included all-cause mortality at Day 28 (<italic toggle="yes">post hoc</italic> for Part 1) and Day 60; time to all-cause mortality up to Day 60; participants alive and free of respiratory failure at Days 7, 14, 42 and 60; time to recovery from respiratory failure at Day 28; time to last dependence on supplementary oxygen up to Day 28; time to final intensive care unit discharge up to Day 28; time to first discharge from investigator site up to Day 60 (revised before unblinding in Part 1); time to first hospital discharge to non-hospitalised residence up to Day 60 (revised before unblinding in Part 1); and adverse events (AEs) and serious AEs (SAEs) up to Day 60. Exploratory end-points are provided in the <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>.</p>
              </sec>
              <sec id="s2e">
                <title>Biomarker and pharmacokinetic assessments</title>
                <p>Blood samples for otilimab and GM-CSF–otilimab complex concentrations were collected on Days 1, 2, 7 and 14. Further details of pharmacokinetic (PK) and exposure-response analyses are provided in the <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>.</p>
                <p>Free GM-CSF was assessed using an ultrasensitive immunoassay based on single molecule array (Simoa™) technology. Target engagement was estimated from the target-mediated drug disposition model [<xref rid="C19" ref-type="bibr">19</xref>] developed using baseline concentrations of free GM-CSF and concentrations of free GM-CSF, otilimab and GM-CSF–otilimab complex over time.</p>
                <p>Blood samples were collected at screening and on Days 2 (Part 1 only), 4 and 7 for measurement of serum concentrations of inflammatory markers using electrochemiluminescence-based immunoassays and neutrophil-to-lymphocyte ratios (NLRs) derived from clinical haematology panels.</p>
              </sec>
              <sec id="s2f">
                <title>Statistical analysis</title>
                <p>Parts 1 and 2 were analysed separately. Full details are provided in the statistical analysis plan (SAP) (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>). Part 1 used a group sequential design to control for multiplicity, with interim analyses for futility and efficacy. In Part 1 and Part 2, a sample size of 800 and 346 patients provided ∼90% and 80% power to detect a difference of 12% and 15%, respectively, in the proportion of patients alive and free of respiratory failure at a one-sided 2.5% significance level and an assumed placebo response rate of 45%.</p>
                <p>The primary end-point was assessed using logistic regression, adjusting for treatment, sex (Part 2 only), age and clinical status at baseline. Missing data in the overall primary analysis were imputed using multiple imputation, assuming data were missing at random and adjusting for analysis covariates. The primary end-point was also analysed in predefined stratification factors based on clinical status, age (<italic toggle="yes">post hoc</italic> in Part 2), clinical status by age (Part 1 only) and sex (Part 2 only), as described in the SAP (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary material</ext-link>).</p>
                <p>Given that OSCAR was a single-dose trial, and dosing was anticipated to occur very quickly following randomisation, it was assumed that any patients who were randomised but did not receive treatment were those who withdrew consent or were randomised in error. Because these patients would have no post-baseline data, the population for primary analyses included all patients who were randomised and received study drug (modified intent-to-treat (mITT)). The SAP was finalised before the clinical database was locked. For ease of interpretation, two-sided p-values with 5% significance level are presented.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Baseline population findings</title>
                <p>In Part 1, 793 patients were included in the mITT population (otilimab n=395; placebo n=398), with patients aged 70–79 years accounting for 23% of the overall population; in Part 2, 347 patients were included in the mITT population (otilimab n=174; placebo n=173) (<xref rid="F1" ref-type="fig">figure 1</xref>). In both parts, baseline demographics and disease characteristics were generally well balanced between groups and were reflective of severe COVID-19 (<xref rid="TB1" ref-type="table">table 1</xref>). Compared with Part 1, a larger proportion of patients in Part 2 were in Category 5.</p>
                <fig position="float" id="F1">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>CONSORT flow diagram in OSCAR study Part 1 (a) and Part 2 (b). mITT: modified intent-to-treat; AE: adverse event. <sup>#</sup>: patients may have more than one reason for failure.</p>
                  </caption>
                  <graphic xlink:href="ERJ-01870-2021.01" position="float"/>
                </fig>
                <table-wrap position="float" id="TB1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Baseline characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td colspan="4" align="center" rowspan="1">
                          <bold>Part 1</bold>
                        </td>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Part 2</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Overall population</bold>
                        </td>
                        <td colspan="2" align="center" rowspan="1"><bold>Age 70–79</bold> <bold>years<sup>#</sup></bold></td>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Overall population</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Characteristic</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (N=403)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (N=403)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (n=88)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (n=92)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (N=175)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (N=175)</bold>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Male sex</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">302 (75)</td>
                        <td align="center" rowspan="1" colspan="1">275 (68)</td>
                        <td align="center" rowspan="1" colspan="1">65 (74)</td>
                        <td align="center" rowspan="1" colspan="1">57 (62)</td>
                        <td align="center" rowspan="1" colspan="1">102 (58)</td>
                        <td align="center" rowspan="1" colspan="1">100 (57)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Age</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">59.8±11.7</td>
                        <td align="center" rowspan="1" colspan="1">59.4±11.9</td>
                        <td align="center" rowspan="1" colspan="1">74.0±2.8</td>
                        <td align="center" rowspan="1" colspan="1">74.0±2.8</td>
                        <td align="center" rowspan="1" colspan="1">75.3±4.7</td>
                        <td align="center" rowspan="1" colspan="1">75.0±4.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Age group</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Part 1:</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> &lt;60 years</td>
                        <td align="center" rowspan="1" colspan="1">178 (44)</td>
                        <td align="center" rowspan="1" colspan="1">185 (46)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 60–69 years</td>
                        <td align="center" rowspan="1" colspan="1">135 (33)</td>
                        <td align="center" rowspan="1" colspan="1">127 (32)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 70–79 years</td>
                        <td align="center" rowspan="1" colspan="1">90 (22)</td>
                        <td align="center" rowspan="1" colspan="1">91 (23)</td>
                        <td align="center" rowspan="1" colspan="1">88 (100)</td>
                        <td align="center" rowspan="1" colspan="1">92 (100)</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Part 2:</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> &lt;70 years<sup>¶</sup></td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 70–79 years</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">126 (72)</td>
                        <td align="center" rowspan="1" colspan="1">136 (78)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> ≥80 years</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">–</td>
                        <td align="center" rowspan="1" colspan="1">40 (23)</td>
                        <td align="center" rowspan="1" colspan="1">34 (19)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Weight (kg)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">88.0±20.9</td>
                        <td align="center" rowspan="1" colspan="1">88.2±20.9</td>
                        <td align="center" rowspan="1" colspan="1">84.6±20.2</td>
                        <td align="center" rowspan="1" colspan="1">80.0±14.2</td>
                        <td align="center" rowspan="1" colspan="1">83.9±16.2</td>
                        <td align="center" rowspan="1" colspan="1">81.9±16.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Race or ethnic group</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> American Indian or Alaska Native</td>
                        <td align="center" rowspan="1" colspan="1">30 (8)</td>
                        <td align="center" rowspan="1" colspan="1">24 (6)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Asian</td>
                        <td align="center" rowspan="1" colspan="1">57 (14)</td>
                        <td align="center" rowspan="1" colspan="1">73 (19)</td>
                        <td align="center" rowspan="1" colspan="1">12 (14)</td>
                        <td align="center" rowspan="1" colspan="1">18 (20)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                        <td align="center" rowspan="1" colspan="1">15 (9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Black or African American</td>
                        <td align="center" rowspan="1" colspan="1">26 (7)</td>
                        <td align="center" rowspan="1" colspan="1">25 (6)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> White</td>
                        <td align="center" rowspan="1" colspan="1">272 (69)</td>
                        <td align="center" rowspan="1" colspan="1">262 (67)</td>
                        <td align="center" rowspan="1" colspan="1">67 (77)</td>
                        <td align="center" rowspan="1" colspan="1">64 (71)</td>
                        <td align="center" rowspan="1" colspan="1">155 (89)</td>
                        <td align="center" rowspan="1" colspan="1">150 (86)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td align="center" rowspan="1" colspan="1">125 (31)</td>
                        <td align="center" rowspan="1" colspan="1">116 (29)</td>
                        <td align="center" rowspan="1" colspan="1">13 (15)</td>
                        <td align="center" rowspan="1" colspan="1">18 (20)</td>
                        <td align="center" rowspan="1" colspan="1">58 (33)</td>
                        <td align="center" rowspan="1" colspan="1">37 (21)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Clinical status</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Category 5: Hospitalised, high-flow oxygen, noninvasive ventilation</td>
                        <td align="center" rowspan="1" colspan="1">311 (77)</td>
                        <td align="center" rowspan="1" colspan="1">311 (77)</td>
                        <td align="center" rowspan="1" colspan="1">63 (72)</td>
                        <td align="center" rowspan="1" colspan="1">68 (74)</td>
                        <td align="center" rowspan="1" colspan="1">150 (86)</td>
                        <td align="center" rowspan="1" colspan="1">148 (85)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Category 6: Hospitalised, mechanical ventilation</td>
                        <td align="center" rowspan="1" colspan="1">89 (22)</td>
                        <td align="center" rowspan="1" colspan="1">89 (22)</td>
                        <td align="center" rowspan="1" colspan="1">24 (27)</td>
                        <td align="center" rowspan="1" colspan="1">23 (25)</td>
                        <td align="center" rowspan="1" colspan="1">25 (14)</td>
                        <td align="center" rowspan="1" colspan="1">27 (15)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>ICU status</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Not in ICU and not on mechanical ventilation</td>
                        <td align="center" rowspan="1" colspan="1">97 (24)</td>
                        <td align="center" rowspan="1" colspan="1">98 (24)</td>
                        <td align="center" rowspan="1" colspan="1">13 (15)</td>
                        <td align="center" rowspan="1" colspan="1">17 (18)</td>
                        <td align="center" rowspan="1" colspan="1">79 (45)</td>
                        <td align="center" rowspan="1" colspan="1">83 (47)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> In ICU and not on mechanical ventilation</td>
                        <td align="center" rowspan="1" colspan="1">209 (52)</td>
                        <td align="center" rowspan="1" colspan="1">211 (52)</td>
                        <td align="center" rowspan="1" colspan="1">49 (56)</td>
                        <td align="center" rowspan="1" colspan="1">52 (57)</td>
                        <td align="center" rowspan="1" colspan="1">69 (39)</td>
                        <td align="center" rowspan="1" colspan="1">62 (35)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> In ICU and on mechanical ventilation</td>
                        <td align="center" rowspan="1" colspan="1">97 (24)</td>
                        <td align="center" rowspan="1" colspan="1">94 (23)</td>
                        <td align="center" rowspan="1" colspan="1">26 (30)</td>
                        <td align="center" rowspan="1" colspan="1">23 (25)</td>
                        <td align="center" rowspan="1" colspan="1">27 (15)</td>
                        <td align="center" rowspan="1" colspan="1">30 (17)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Biomarkers</bold>
                          <sup>+</sup>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> CRP (mg·L<sup>−1</sup>)</td>
                        <td align="center" rowspan="1" colspan="1">111.8±86.0</td>
                        <td align="center" rowspan="1" colspan="1">116.3±84.5</td>
                        <td align="center" rowspan="1" colspan="1">109.7±79</td>
                        <td align="center" rowspan="1" colspan="1">128.8±82.2</td>
                        <td align="center" rowspan="1" colspan="1">96.1±79.4</td>
                        <td align="center" rowspan="1" colspan="1">93.5±77.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Ferritin (μg·L<sup>−1</sup>)</td>
                        <td align="center" rowspan="1" colspan="1">1247.7±1242.9</td>
                        <td align="center" rowspan="1" colspan="1">1147.4±1041.6</td>
                        <td align="center" rowspan="1" colspan="1">1493.1±1916</td>
                        <td align="center" rowspan="1" colspan="1">1248.4±1201.3</td>
                        <td align="center" rowspan="1" colspan="1">1482.3±1697.3</td>
                        <td align="center" rowspan="1" colspan="1">1177.4±1060.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> GM-CSF (ng·L<sup>−1</sup>)</td>
                        <td align="center" rowspan="1" colspan="1">0.71±0.84</td>
                        <td align="center" rowspan="1" colspan="1">0.72±0.76</td>
                        <td align="center" rowspan="1" colspan="1">0.82±1.19</td>
                        <td align="center" rowspan="1" colspan="1">0.73±0.71</td>
                        <td align="center" rowspan="1" colspan="1">0.82±1.44</td>
                        <td align="center" rowspan="1" colspan="1">0.80±0.95</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Residence prior to hospital admission</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Independent or community dwelling</td>
                        <td align="center" rowspan="1" colspan="1">392 (98)</td>
                        <td align="center" rowspan="1" colspan="1">391 (97)</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">173 (99)</td>
                        <td align="center" rowspan="1" colspan="1">169 (97)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Long-term care facility</td>
                        <td align="center" rowspan="1" colspan="1">7 (2)</td>
                        <td align="center" rowspan="1" colspan="1">10 (2)</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">2 (1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Current comorbidity</bold>
                          <sup>§</sup>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                        <td align="center" rowspan="1" colspan="1">192 (48)</td>
                        <td align="center" rowspan="1" colspan="1">209 (52)</td>
                        <td align="center" rowspan="1" colspan="1">59 (67)</td>
                        <td align="center" rowspan="1" colspan="1">61 (66)</td>
                        <td align="center" rowspan="1" colspan="1">113 (65)</td>
                        <td align="center" rowspan="1" colspan="1">129 (74)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Diabetes</td>
                        <td align="center" rowspan="1" colspan="1">147 (36)</td>
                        <td align="center" rowspan="1" colspan="1">149 (37)</td>
                        <td align="center" rowspan="1" colspan="1">31 (35)</td>
                        <td align="center" rowspan="1" colspan="1">39 (42)</td>
                        <td align="center" rowspan="1" colspan="1">57 (33)</td>
                        <td align="center" rowspan="1" colspan="1">63 (36)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hyperlipidaemia</td>
                        <td align="center" rowspan="1" colspan="1">97 (24)</td>
                        <td align="center" rowspan="1" colspan="1">96 (24)</td>
                        <td align="center" rowspan="1" colspan="1">35 (40)</td>
                        <td align="center" rowspan="1" colspan="1">41 (45)</td>
                        <td align="center" rowspan="1" colspan="1">45 (26)</td>
                        <td align="center" rowspan="1" colspan="1">53 (30)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Heart disorder</td>
                        <td align="center" rowspan="1" colspan="1">51 (13)</td>
                        <td align="center" rowspan="1" colspan="1">45 (11)</td>
                        <td align="center" rowspan="1" colspan="1">21 (24)</td>
                        <td align="center" rowspan="1" colspan="1">21 (23)</td>
                        <td align="center" rowspan="1" colspan="1">35 (20)</td>
                        <td align="center" rowspan="1" colspan="1">47 (27)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Pretreatment medications</bold>
                          <sup>§</sup>
                          <sup>,<sup>ƒ</sup></sup>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Corticosteroids (including dexamethasone)</td>
                        <td align="center" rowspan="1" colspan="1">332 (84)</td>
                        <td align="center" rowspan="1" colspan="1">330 (83)</td>
                        <td align="center" rowspan="1" colspan="1">72 (82)</td>
                        <td align="center" rowspan="1" colspan="1">74 (80)</td>
                        <td align="center" rowspan="1" colspan="1">150 (86)</td>
                        <td align="center" rowspan="1" colspan="1">148 (86)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Dexamethasone</td>
                        <td align="center" rowspan="1" colspan="1">281 (71)</td>
                        <td align="center" rowspan="1" colspan="1">267 (67)</td>
                        <td align="center" rowspan="1" colspan="1">64 (73)</td>
                        <td align="center" rowspan="1" colspan="1">66 (72)</td>
                        <td align="center" rowspan="1" colspan="1">137 (79)</td>
                        <td align="center" rowspan="1" colspan="1">125 (72)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Remdesivir</td>
                        <td align="center" rowspan="1" colspan="1">127 (32)</td>
                        <td align="center" rowspan="1" colspan="1">142 (36)</td>
                        <td align="center" rowspan="1" colspan="1">28 (32)</td>
                        <td align="center" rowspan="1" colspan="1">32 (35)</td>
                        <td align="center" rowspan="1" colspan="1">12 (7)</td>
                        <td align="center" rowspan="1" colspan="1">22 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Convalescent plasma therapy</td>
                        <td align="center" rowspan="1" colspan="1">20 (5)</td>
                        <td align="center" rowspan="1" colspan="1">24 (6)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Immunosuppressants</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Anti-IL-6 therapies</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)<sup>##</sup></td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Antiviral</td>
                        <td align="center" rowspan="1" colspan="1">136 (34)</td>
                        <td align="center" rowspan="1" colspan="1">155 (39)</td>
                        <td align="center" rowspan="1" colspan="1">29 (33)</td>
                        <td align="center" rowspan="1" colspan="1">38 (41)</td>
                        <td align="center" rowspan="1" colspan="1">29 (17)</td>
                        <td align="center" rowspan="1" colspan="1">44 (25)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> COVID-19 vaccine</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">NA</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Geographic region</bold>
                          <sup>§</sup>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> USA</td>
                        <td align="center" rowspan="1" colspan="1">98 (24)</td>
                        <td align="center" rowspan="1" colspan="1">90 (22)</td>
                        <td align="center" rowspan="1" colspan="1">20 (23)</td>
                        <td align="center" rowspan="1" colspan="1">23 (25)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Europe<sup>¶¶</sup></td>
                        <td align="center" rowspan="1" colspan="1">142 (35)</td>
                        <td align="center" rowspan="1" colspan="1">160 (40)</td>
                        <td align="center" rowspan="1" colspan="1">41 (47)</td>
                        <td align="center" rowspan="1" colspan="1">38 (41)</td>
                        <td align="center" rowspan="1" colspan="1">69 (39)</td>
                        <td align="center" rowspan="1" colspan="1">78 (45)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Latin America<sup>++</sup></td>
                        <td align="center" rowspan="1" colspan="1">68 (17)</td>
                        <td align="center" rowspan="1" colspan="1">53 (13)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">53 (30)</td>
                        <td align="center" rowspan="1" colspan="1">31 (18)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Rest of world<sup>§§</sup></td>
                        <td align="center" rowspan="1" colspan="1">95 (24)</td>
                        <td align="center" rowspan="1" colspan="1">100 (25)</td>
                        <td align="center" rowspan="1" colspan="1">19 (22)</td>
                        <td align="center" rowspan="1" colspan="1">23 (25)</td>
                        <td align="center" rowspan="1" colspan="1">44 (25)</td>
                        <td align="center" rowspan="1" colspan="1">49 (28)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Data are presented as n (%) or mean±<sc>sd</sc>. ICU: intensive care unit; CRP: C-reactive protein; GM-CSF: granulocyte–macrophage colony-stimulating factor; IL: interleukin; NA: not available. <sup>#</sup>: baseline characteristics in the Part 1 age 70–79 years subgroup are presented in the modified intent-to-treat population; <sup>¶</sup>: patient age was derived from the date of screening visit, year of birth (provided at screening) and an assumed birth date of June 30, and so some patients were recorded as &lt;70 years; <sup>+</sup>: biomarkers summarised by actual treatment received; <sup>§</sup>: data in the Part 1 age 70–79 years group are from Day 4; <sup>ƒ</sup>: a dose or infusion of medication used prior to Day 1 (day of dosing of study drug), irrespective of whether medication continued after dosing; <sup>##</sup>: one patient who had received anti-IL-6 therapy was included in error; <sup>¶¶</sup>: Belgium, France, Italy, Netherlands, Poland, Spain, UK; <sup>++</sup>: Argentina, Brazil, Chile, Colombia, Mexico, Peru; <sup>§§</sup>: Canada, India, Japan, Russian Federation, South Africa.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s3b">
                <title>Primary end-point: patients alive and free of respiratory failure</title>
                <p>In Part 1, 71% of patients in the otilimab group were alive and free of respiratory failure at Day 28 <italic toggle="yes">versus</italic> 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI −0.8­–11.4%, p=0.09) (<xref rid="F2" ref-type="fig">figure 2a</xref>). Model-adjusted differences for patients in Categories 5 and 6 were 5.9% (95% CI −0.8­–12.7%) and 4.6% (95% CI −9.6–18.8%), respectively (<xref rid="F2" ref-type="fig">figure 2a</xref>). In the predefined subgroup of patients aged 70–79 years, the model-adjusted difference was 19.1% (95% CI 5.2–33.1%, nominal p=0.009); this response was consistent regardless of clinical status (<xref rid="F2" ref-type="fig">figure 2a</xref>).</p>
                <fig position="float" id="F2">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Proportion of patients alive and free of respiratory failure at Day 28 in a) Part 1 and b) Part 2 (primary end-point). <sup>#</sup>: analysis of the primary end-point in patients by clinical status at baseline stratified by age group was not conducted in Part 2 owing to the low number of patients aged ≥80 years.</p>
                  </caption>
                  <graphic xlink:href="ERJ-01870-2021.02" position="float"/>
                </fig>
                <p>In Part 2, 52% of patients who received otilimab were alive and free of respiratory failure at Day 28 <italic toggle="yes">versus</italic> 51% who received placebo (model-adjusted difference: 0.9%, 95% CI −9.3–11.2%, p=0.86) (<xref rid="F2" ref-type="fig">figure 2b</xref>). For patients in Categories 5 and 6, the model-adjusted difference was 4.2% (95% CI −6.9–15.4%) and −17.5% (95% CI −42.7–7.6%), respectively (<xref rid="F2" ref-type="fig">figure 2b</xref>). Model-adjusted differences were −2.1% (95% CI −14.0–9.8%, p=0.73) in patients aged 70–&lt;80 years and 7.7% (95% CI −14.7–30.2%, p=0.51) in patients aged ≥80 years (<xref rid="F2" ref-type="fig">figure 2b</xref>). <italic toggle="yes">Post hoc</italic> analyses of the primary end-point by baseline characteristic are presented in <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S1</ext-link>.</p>
              </sec>
              <sec id="s3c">
                <title>Secondary end-point: all-cause mortality</title>
                <p>In Part 1, all-cause mortality at Day 60 was 23% in the otilimab group compared with 24% in the placebo group (model-adjusted difference −2.4%, 95% CI −8.0–3.3%, p=0.41) (<xref rid="F3" ref-type="fig">figure 3a</xref>). In the 70–79 years subgroup, there was lower mortality at Day 60 with otilimab (27%) <italic toggle="yes">versus</italic> placebo (41%) (model-adjusted difference −14.4%, 95% CI −27.9– −0.9%, nominal p=0.04).</p>
                <fig position="float" id="F3">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>All-cause mortality in a) Part 1 at Day 28 (<italic toggle="yes">post hoc</italic><sup>#</sup>) and Day 60 (pre-specified), and in b) Part 2 at Day 28 and Day 60 (pre-specified). <sup>#</sup>: Day 28 analysis in Part 1 was conducted <italic toggle="yes">post hoc</italic>, thus data are not available by clinical status at baseline.</p>
                  </caption>
                  <graphic xlink:href="ERJ-01870-2021.03" position="float"/>
                </fig>
                <p>In Part 2, all-cause mortality at Day 28 was 37% in the otilimab group compared with 41% in the placebo group (model-adjusted difference −5.2%, 95% CI −15.1–4.7%, p=0.31) (<xref rid="F3" ref-type="fig">figure 3b</xref>). Mortality at Day 60 was 43% in the otilimab group and 45% in the placebo group, with a model-adjusted difference of −2.2% (95% CI −12.4–7.9%, p=0.67). No significant differences in mortality at Days 28 or 60 were observed in the predefined subgroups of either part.</p>
              </sec>
              <sec id="s3d">
                <title>Additional secondary and exploratory efficacy end-points</title>
                <p>Generally, there were no significant differences in time-to-event analyses in the Part 1 mITT population between treatment groups (<xref rid="F4" ref-type="fig">figures 4a</xref> and 5a, <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S2a–g</ext-link>). However, improvements with otilimab <italic toggle="yes">versus</italic> placebo were observed in the 70–79 years subgroup (<xref rid="F4" ref-type="fig">figures 4b</xref> and 5b, <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S2a–d</ext-link>), with treatment effects apparent 7–10 days post-infusion.</p>
                <fig position="float" id="F4">
                  <label>FIGURE 4</label>
                  <caption>
                    <p>Kaplan–Meier time to recovery from respiratory failure up to Day 28 in the a) modified intent-to-treat (mITT) population and b) <italic toggle="yes">post hoc</italic> 70–79 years group of Part 1, and c) in the mITT population of Part 2 (secondary end-point).</p>
                  </caption>
                  <graphic xlink:href="ERJ-01870-2021.04" position="float"/>
                </fig>
                <p>There was a short-term numerical benefit of otilimab <italic toggle="yes">versus</italic> placebo in most time-to-event analyses in Part 2, including time to recovery from respiratory failure, as well as an early delay in time to invasive mechanical ventilation; separation between groups was observed from around Day 3 and they converged around Day 10 (<xref rid="F4" ref-type="fig">figure 4c</xref>, <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S2a, b, e, g</ext-link>). There was no difference between otilimab and placebo in time to all-cause mortality up to Day 60 (<xref rid="F5" ref-type="fig">figure 5c</xref>).</p>
                <fig position="float" id="F5">
                  <label>FIGURE 5</label>
                  <caption>
                    <p>Kaplan–Meier time to all-cause mortality up to Day 60 in the a) modified intent-to-treat (mITT) population and b) <italic toggle="yes">post hoc</italic> 70–79 years group of Part 1, and c) in the mITT population of Part 2 (secondary end-point).</p>
                  </caption>
                  <graphic xlink:href="ERJ-01870-2021.05" position="float"/>
                </fig>
                <p>In the exploratory end-point of change from baseline in inspiratory oxygen fraction (<italic toggle="yes">F</italic><sub>iO<sub>2</sub></sub>), a greater reduction was observed in patients receiving otilimab <italic toggle="yes">versus</italic> placebo in the Part 1 mITT population, Part 1 70–79 years subgroup and Part 2 mITT population up to Day 14 (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S2h</ext-link>).</p>
              </sec>
              <sec id="s3e">
                <title>Safety end-points</title>
                <p>In both parts, no safety signals related to otilimab were identified. Overall safety findings, including the scope of AEs and SAEs, were reflective of the severe COVID-19 population, and no clinically meaningful differences in AEs, including the rates of secondary infections, were observed (<xref rid="TB2" ref-type="table">table 2</xref>).</p>
                <table-wrap position="float" id="TB2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Adverse events</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td colspan="4" align="center" rowspan="1">
                          <bold>Part 1</bold>
                        </td>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Part 2</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="2" valign="bottom" align="left" colspan="1">
                          <bold>AE</bold>
                        </td>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Safety population</bold>
                        </td>
                        <td colspan="2" align="center" rowspan="1"><bold>Age 70–79</bold> <bold>years</bold></td>
                        <td colspan="2" align="center" rowspan="1">
                          <bold>Safety population</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (n=397)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (n=396)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (n=89)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (n=91)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Otilimab (n=174)</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Placebo (n=173)</bold>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any AE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Patients with ≥1 event</td>
                        <td align="center" rowspan="1" colspan="1">274 (69)</td>
                        <td align="center" rowspan="1" colspan="1">265 (67)</td>
                        <td align="center" rowspan="1" colspan="1">73 (82)</td>
                        <td align="center" rowspan="1" colspan="1">68 (75)</td>
                        <td align="center" rowspan="1" colspan="1">140 (80)</td>
                        <td align="center" rowspan="1" colspan="1">133 (77)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Any SAE</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Patients with ≥1 event</td>
                        <td align="center" rowspan="1" colspan="1">124 (31)</td>
                        <td align="center" rowspan="1" colspan="1">147 (37)</td>
                        <td align="center" rowspan="1" colspan="1">33 (37)</td>
                        <td align="center" rowspan="1" colspan="1">49 (54)</td>
                        <td align="center" rowspan="1" colspan="1">90 (52)</td>
                        <td align="center" rowspan="1" colspan="1">90 (52)</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Most common AEs ≥5% in any group</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Constipation</td>
                        <td align="center" rowspan="1" colspan="1">39 (10)</td>
                        <td align="center" rowspan="1" colspan="1">35 (9)</td>
                        <td align="center" rowspan="1" colspan="1">16 (18)</td>
                        <td align="center" rowspan="1" colspan="1">14 (15)</td>
                        <td align="center" rowspan="1" colspan="1">16 (9)</td>
                        <td align="center" rowspan="1" colspan="1">15 (9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pneumonia</td>
                        <td align="center" rowspan="1" colspan="1">43 (11)</td>
                        <td align="center" rowspan="1" colspan="1">29 (7)</td>
                        <td align="center" rowspan="1" colspan="1">13 (15)</td>
                        <td align="center" rowspan="1" colspan="1">11 (12)</td>
                        <td align="center" rowspan="1" colspan="1">12 (7)</td>
                        <td align="center" rowspan="1" colspan="1">17 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Acute kidney injury</td>
                        <td align="center" rowspan="1" colspan="1">23 (6)</td>
                        <td align="center" rowspan="1" colspan="1">25 (6)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">11 (12)</td>
                        <td align="center" rowspan="1" colspan="1">14 (8)</td>
                        <td align="center" rowspan="1" colspan="1">12 (7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Anaemia</td>
                        <td align="center" rowspan="1" colspan="1">18 (5)</td>
                        <td align="center" rowspan="1" colspan="1">22 (6)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">11 (6)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Respiratory failure</td>
                        <td align="center" rowspan="1" colspan="1">19 (5)</td>
                        <td align="center" rowspan="1" colspan="1">21 (5)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">9 (10)</td>
                        <td align="center" rowspan="1" colspan="1">7 (4)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypotension</td>
                        <td align="center" rowspan="1" colspan="1">14 (4)</td>
                        <td align="center" rowspan="1" colspan="1">16 (4)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                        <td align="center" rowspan="1" colspan="1">13 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Atrial fibrillation</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">18 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">9 (10)</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                        <td align="center" rowspan="1" colspan="1">12 (7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Septic shock</td>
                        <td align="center" rowspan="1" colspan="1">18 (5)</td>
                        <td align="center" rowspan="1" colspan="1">16 (4)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pulmonary embolism</td>
                        <td align="center" rowspan="1" colspan="1">13 (3)</td>
                        <td align="center" rowspan="1" colspan="1">25 (6)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">9 (10)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                        <td align="center" rowspan="1" colspan="1">7 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypoxaemia</td>
                        <td align="center" rowspan="1" colspan="1">10 (3)</td>
                        <td align="center" rowspan="1" colspan="1">13 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                        <td align="center" rowspan="1" colspan="1">12 (7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> MODS</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">16 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">11 (6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypokalaemia</td>
                        <td align="center" rowspan="1" colspan="1">15 (4)</td>
                        <td align="center" rowspan="1" colspan="1">16 (4)</td>
                        <td align="center" rowspan="1" colspan="1">7 (8)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Diarrhoea</td>
                        <td align="center" rowspan="1" colspan="1">15 (4)</td>
                        <td align="center" rowspan="1" colspan="1">18 (5)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> UTI</td>
                        <td align="center" rowspan="1" colspan="1">13 (3)</td>
                        <td align="center" rowspan="1" colspan="1">14 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pneumothorax</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">15 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pyrexia</td>
                        <td align="center" rowspan="1" colspan="1">20 (5)</td>
                        <td align="center" rowspan="1" colspan="1">15 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hyperglycaemia</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">14 (4)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Delirium</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                        <td align="center" rowspan="1" colspan="1">2 (1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hyperkalaemia</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">13 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">7 (8)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                        <td align="center" rowspan="1" colspan="1">4 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">10 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Acute respiratory failure</td>
                        <td align="center" rowspan="1" colspan="1">10 (3)</td>
                        <td align="center" rowspan="1" colspan="1">11 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hepatocellular injury</td>
                        <td align="center" rowspan="1" colspan="1">6 (2)</td>
                        <td align="center" rowspan="1" colspan="1">5 (1)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">14 (9)</td>
                        <td align="center" rowspan="1" colspan="1">10 (6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypernatraemia</td>
                        <td align="center" rowspan="1" colspan="1">20 (5)</td>
                        <td align="center" rowspan="1" colspan="1">10 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Insomnia</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (1)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                        <td align="center" rowspan="1" colspan="1">7 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Sepsis</td>
                        <td align="center" rowspan="1" colspan="1">7 (2)</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Decubitus ulcer</td>
                        <td align="center" rowspan="1" colspan="1">16 (4)</td>
                        <td align="center" rowspan="1" colspan="1">9 (2)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Fluid overload</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">2 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Most common SAEs ≥5% any group</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Respiratory failure</td>
                        <td align="center" rowspan="1" colspan="1">17 (4)</td>
                        <td align="center" rowspan="1" colspan="1">18 (5)</td>
                        <td align="center" rowspan="1" colspan="1">6 (7)</td>
                        <td align="center" rowspan="1" colspan="1">8 (9)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> MODS</td>
                        <td align="center" rowspan="1" colspan="1">12 (3)</td>
                        <td align="center" rowspan="1" colspan="1">15 (4)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Septic shock</td>
                        <td align="center" rowspan="1" colspan="1">14 (4)</td>
                        <td align="center" rowspan="1" colspan="1">13 (3)</td>
                        <td align="center" rowspan="1" colspan="1">4 (4)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">8 (5)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Acute respiratory failure</td>
                        <td align="center" rowspan="1" colspan="1">9 (2)</td>
                        <td align="center" rowspan="1" colspan="1">10 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (6)</td>
                        <td align="center" rowspan="1" colspan="1">3 (3)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pneumonia</td>
                        <td align="center" rowspan="1" colspan="1">7 (2)</td>
                        <td align="center" rowspan="1" colspan="1">9 (2)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">5 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> COVID-19<sup>#</sup></td>
                        <td align="center" rowspan="1" colspan="1">3 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">5 (1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (3)</td>
                        <td align="center" rowspan="1" colspan="1">9 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pulmonary embolism</td>
                        <td align="center" rowspan="1" colspan="1">6 (2)</td>
                        <td align="center" rowspan="1" colspan="1">11 (3)</td>
                        <td align="center" rowspan="1" colspan="1">2 (2)</td>
                        <td align="center" rowspan="1" colspan="1">5 (5)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Patients with AEs of special interest</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Serious infections</td>
                        <td align="center" rowspan="1" colspan="1">50 (13)</td>
                        <td align="center" rowspan="1" colspan="1">58 (15)</td>
                        <td align="center" rowspan="1" colspan="1">12 (13)</td>
                        <td align="center" rowspan="1" colspan="1">17 (19)</td>
                        <td align="center" rowspan="1" colspan="1">37 (21)</td>
                        <td align="center" rowspan="1" colspan="1">29 (17)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Cytokine release syndrome</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">2 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">3 (2)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Serious hypersensitivity reactions</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Infusion site reactions</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">1 (1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Neutropaenia</td>
                        <td align="center" rowspan="1" colspan="1">1 (&lt;1)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Data are presented as n (%). AE: adverse event; SAE: serious adverse event; MODS: multiple organ dysfunction syndrome; UTI: urinary tract infection. <sup>#</sup>: COVID-19, as per protocol, was only to be reported as an AE if the signs and symptoms of COVID-19 were more severe than expected.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s3f">
                <title>Biomarkers</title>
                <p>Similar free GM-CSF concentrations were observed in both parts at baseline and Day 1 (<xref rid="TB1" ref-type="table">table 1</xref> and <ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary table S1</ext-link>). In Part 1, free GM-CSF levels in the otilimab arm at Day 2, proximal to maximum concentration (C<sub>max</sub>), were reduced by at least 95% to a mean of 0.037 ng·L<sup>−1</sup><sub>,</sub> with 255 of 381 samples (67%) falling below the assay lower limit of quantification (0.036 ng·L<sup>−1</sup>); levels in the placebo arm remained unchanged. Day 2 data were not collected in Part 2, and post-Day 2 data are not available.</p>
                <p>Otilimab also induced rapid reductions in other key inflammatory markers compared with placebo in the 7 days after infusion (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S3</ext-link>). Data from the 70–79 years subgroup of Part 1 were similar to the total Part 1 population. In both parts, greater reductions in interleukin (IL)-6 and IL-10 were observed with otilimab <italic toggle="yes">versus</italic> placebo at Day 2 and/or 4, converging by Day 7. CRP concentrations decreased from baseline in both groups, although Part 2 showed greater reductions with otilimab by Day 7. CC chemokine ligand 17 (CCL17) concentrations increased in the placebo group, but not in the otilimab group in both parts, and a greater reduction from baseline in NLR was observed with otilimab at Days 4 and 7 in Part 2; however, the effect with placebo varied between study parts, as did the patterns observed for macrophage chemotactic protein-1 (MCP-1) and IL-8.</p>
              </sec>
              <sec id="s3g">
                <title>PK</title>
                <p>Similar serum concentrations of otilimab (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S4 and table S1</ext-link>) and GM-CSF–otilimab complex concentrations (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S5 and table S1</ext-link>) were observed in both parts. The target engagement model predicted 91%, 74% and 23% target engagement at Days 2, 4 and 7, respectively.</p>
                <p>Across all patients in both parts, the PK model-derived mean otilimab exposure parameters C<sub>max</sub> and area under the concentration-time curve (AUC), following a single dose of 90 mg, were 18.9 μg·mL<sup>−1</sup> and 50.7 μg·day·mL<sup>−1</sup>, respectively. The population clearance rate of otilimab was 1.67 L·day<sup>−1</sup>, and effective half-life was 3.65 days.</p>
                <p>Clinical response (patients alive and free of respiratory failure on Day 28, all-cause mortality at Day 60 and improvements in clinical status over time) when stratified by placebo and quartile of otilimab exposure (AUC or C<sub>max</sub>) suggested that a higher otilimab exposure was associated with better response (<ext-link xlink:href="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01870-2021.figures-only#fig-data-supplementary-materials" ext-link-type="uri">supplementary figure S6</ext-link>); however, patients in the lowest quartile group had a worse response than those in the placebo group. Day 7 and 14 data for the proportion of patients alive and free of respiratory failure were similar to Day 28 data. There was no clear relationship between exposure and serious infection or change in CRP, IL-6, CCL17 or MCP-1.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>In this large study of hospitalised adults with COVID-19 aged 18–79 years (Part 1) and ≥70 years (Part 2), administration of otilimab was not associated with a significant difference in the proportion of patients alive and free of respiratory failure at Day 28.</p>
              <p>In Part 1, otilimab was associated with a nonsignificant increase in the proportion of patients alive and free of respiratory failure at Day 28. However, significantly more patients in a predefined subgroup aged 70–79 years receiving otilimab met this end-point compared with those receiving placebo. There was also a corresponding decrease in all-cause mortality at Day 60. Immunosenescence and “inflammaging”, associated with normal ageing of the immune system, may predispose older patients with COVID-19 to inappropriate, myeloid cell-driven hyperinflammation [<xref rid="C5" ref-type="bibr">5</xref>, <xref rid="C6" ref-type="bibr">6</xref>]. Further evidence emerged at the time of the Part 1 analysis that supported the potential role of GM-CSF and myeloid cells in COVID-19 pathogenesis [<xref rid="C10" ref-type="bibr">10</xref>–<xref rid="C13" ref-type="bibr">13</xref>].</p>
              <p>Based on Part 1 findings and the high mortality rate observed in older patients with severe COVID-19 [<xref rid="C9" ref-type="bibr">9</xref>], Part 2 specifically evaluated the potential clinical benefit in patients aged ≥70 years. This extension of the study did not, however, confirm the significant difference between otilimab and placebo for the primary end-point observed in Part 1. Despite a credible hypothesis, it is likely that observations in a single subgroup in Part 1 were due to chance. Other confounding factors may have also contributed to the differences in results, including slight variations in patient demographics, risk profiles and clinical status between parts, in addition to variability in mortality rates across geographies [<xref rid="C20" ref-type="bibr">20</xref>], improvements in standard of care and patient management, and the changing prevalence and virulence of viral variants [<xref rid="C21" ref-type="bibr">21</xref>] at the different stages of the pandemic. Additional study limitations include the use of an estimated birth date (with only the year of birth recorded) to determine patient age and low patient numbers in certain subgroups, which made it difficult to perform some sub-analyses.</p>
              <p>Low systemic target engagement levels after Day 4 may have impacted efficacy. However, patients with the lowest otilimab exposure generally had a worse clinical response than placebo-treated patients. This suggests a potential bidirectional interaction between PK and response, whereby patients with more severe disease have increased otilimab clearance, causing an apparent exposure-response relationship. Thus, exposure-response data cannot indicate whether a higher dose of otilimab would provide any additional benefit. Furthermore, while a potential early benefit in respiratory status was observed within the first ∼10 days of dosing in Part 2, the apparent benefit in the ≥70 years subgroup in Part 1 was only observed after Day 10, despite a decrease in otilimab concentration over Days 1–7, suggesting a delay in treatment effect. Therefore, multiple doses may not have been more effective. However, given that the findings of an overall benefit in most of the time-to-event analyses through to Day 28 in the ≥70 years subgroup of Part 1 were not replicated in Part 2 (except for decreased <italic toggle="yes">F</italic><sub>iO<sub>2</sub></sub> requirement), despite a similar population, the observed differences between parts during the early stages of the studies are unlikely to be real.</p>
              <p>In both parts of OSCAR, otilimab treatment resulted in lower concentrations of the putative pharmacodynamic biomarker for otilimab activity, CCL17 [<xref rid="C22" ref-type="bibr">22</xref>], in the 7 days post-infusion with no convergence with placebo, indicating successful target engagement and inhibition of pathways downstream of GM-CSF. Inflammatory markers IL-6 and IL-10 are generally increased in hospitalised patients with COVID-19 and are associated with disease severity [<xref rid="C23" ref-type="bibr">23</xref>]. In the RECOVERY study, inhibition of IL-6 reduced mortality and improved clinical outcomes [<xref rid="C24" ref-type="bibr">24</xref>]. The reduction in these cytokines observed with otilimab may be associated with the delay in clinical deterioration observed in the first week in Part 2. However, the otilimab group converged with placebo by Day 7, coinciding with the decrease in target engagement from 95% at the end of infusion to 23% by Day 7. This could be due to the shorter than previously observed effective half-life of otilimab in patients with COVID-19.</p>
              <p>Elevated NLR is a predictor for critical disease [<xref rid="C25" ref-type="bibr">25</xref>], and neutrophils have been proposed to have an important role in COVID-19 pneumonia [<xref rid="C2" ref-type="bibr">2</xref>, <xref rid="C4" ref-type="bibr">4</xref>, <xref rid="C26" ref-type="bibr">26</xref>]. Otilimab was associated with decreased NLR from baseline up to Day 7 in Part 2, which suggests an early reduction in circulating neutrophil numbers and/or repopulation of lymphocytes and potential dampening of the hyperinflammatory response following GM-CSF inhibition [<xref rid="C26" ref-type="bibr">26</xref>, <xref rid="C27" ref-type="bibr">27</xref>]. Because all observed biomarker changes were systemic, it is unclear whether these changes were reflected in the lungs, where multiple mechanisms may lead to lung injury.</p>
              <p>The lack of a clinically meaningful benefit of otilimab in this severe COVID-19 population may be due to the highly complex and only partially characterised multiplicity of cytokines, chemokines and cellular components involved in COVID-19 pathophysiology. With new evidence continually emerging, combination therapies, targeting multiple pathways [<xref rid="C28" ref-type="bibr">28</xref>, <xref rid="C29" ref-type="bibr">29</xref>], have been adopted into treatment regimens and guidelines [<xref rid="C1" ref-type="bibr">1</xref>]. Furthermore, the timing of intervention may be key. OSCAR included patients with already profound respiratory failure and systemic hyperinflammation. However, a window of opportunity may exist in the early stage of hyperinflammation, before progression to significant respiratory failure [<xref rid="C11" ref-type="bibr">11</xref>]. This is suggested by the results of the LIVE-AIR study in which anti-GM-CSF lenzilumab was less effective in patients with higher CRP concentrations [<xref rid="C30" ref-type="bibr">30</xref>]. Both parts of OSCAR demonstrated the ability of otilimab to decrease <italic toggle="yes">F</italic><sub>iO<sub>2</sub></sub> more rapidly in all age groups to Day 12–14. This apparent improvement in gaseous exchange in the lungs was not, however, associated with improved clinical outcomes.</p>
              <p>Recent <italic toggle="yes">in vitro</italic> studies suggest that binding of the SARS-CoV-2 spike protein to circulating mononuclear cells directly induces GM-CSF secretion, providing further evidence of a role for GM-CSF in the immune response to the virus [<xref rid="C31" ref-type="bibr">31</xref>]. However, clinical anti-GM-CSF therapy has generated mixed results in various COVID-19 trials. The anti-GM-CSF receptor α subunit mavrilimumab demonstrated efficacy in a phase 2 trial [<xref rid="C32" ref-type="bibr">32</xref>]; however, the phase 3 trial did not meet the primary end-point, leading to its discontinuation in COVID-19 [<xref rid="C33" ref-type="bibr">33</xref>]. Anti-GM-CSF namilumab demonstrated a reduction in CRP in the CATALYST trial and trends towards clinical improvement, but the study was not powered for these outcomes [<xref rid="C34" ref-type="bibr">34</xref>]. Finally, while LIVE-AIR demonstrated that early intervention with lenzilumab decreases CRP and improves the likelihood of survival without ventilation [<xref rid="C30" ref-type="bibr">30</xref>, <xref rid="C35" ref-type="bibr">35</xref>], this was not supported by the ACTIV-5/BET-B trial of lenzilumab plus remdesivir, which failed to meet the same primary end-point of survival without ventilation [<xref rid="C36" ref-type="bibr">36</xref>]. Furthermore, lenzilumab did not significantly improve mortality rates in the overall population of either trial [<xref rid="C30" ref-type="bibr">30</xref>, <xref rid="C36" ref-type="bibr">36</xref>]. This inconclusive evidence for the benefit of anti-GM-CSF monotherapy in COVID-19 may be linked to the varying disease severity of the patient populations and the different end-points used in the different studies. Nevertheless, inflammatory biomarker findings in OSCAR continue to support the ongoing evaluation of otilimab in other immune-inflammatory conditions. Indeed, following two phase 2 studies in RA [<xref rid="C16" ref-type="bibr">16</xref>, <xref rid="C22" ref-type="bibr">22</xref>], a large global phase 3 RA programme is ongoing [<xref rid="C37" ref-type="bibr">37</xref>–<xref rid="C39" ref-type="bibr">39</xref>].</p>
              <p>The AE rate for OSCAR was as expected for a population with severe COVID-19 pneumonia, with the most common SAE being respiratory failure. No clinically meaningful difference was observed between all AEs, including, importantly, the rates of COVID secondary infections, and no safety signals related to otilimab treatment were identified.</p>
              <p>Treatment with a single dose of otilimab did not improve the proportion of patients alive and free of respiratory failure at Day 28. Target engagement and a reduction in inflammatory markers were observed, in addition to an acceptable safety profile in a severely ill patient population.</p>
            </sec>
            <sec id="s5">
              <title>Supplementary material</title>
              <supplementary-material id="supplementary" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1183/13993003.01870-2021.Supp1</object-id>
                <p><bold>Please note:</bold> supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.</p>
                <p>Supplementary material <inline-supplementary-material id="SS1" xlink:href="ERJ-01870-2021.SUPPLEMENT.pdf" content-type="local-data">ERJ-01870-2021.SUPPLEMENT</inline-supplementary-material></p>
              </supplementary-material>
            </sec>
            <sec id="s6">
              <title>Shareable PDF</title>
              <supplementary-material id="shareable" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1183/13993003.01870-2021.Shareable1</object-id>
                <p>This one-page PDF can be shared freely online.</p>
                <p>Shareable PDF <inline-supplementary-material id="SS2" xlink:href="ERJ-01870-2021.Shareable.pdf" content-type="local-data">ERJ-01870-2021.Shareable</inline-supplementary-material>
</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank all the patients for their participation in this important research. We thank Gift Nyamundanda and Johannes Freudenberg for their work on the biomarker analyses; the global clinical operations delivery managers, Kai Hove and Jack Siderfin; and the global study data managers, Sam Birleson, Laurence Harvey and Oyiza Momoh. Medical writing support, in the form of editorial checks, figure development and assistance with submission, was provided by Leigh O'Connor-Jones and Clare Cunningham of Fishawack Indicia Ltd UK, part of Fishawack Health (funded by GSK).</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p>This clinical trial has been prospectively registered as NCT04376684. GSK makes available anonymised individual participant data and associated documents from interventional clinical studies which evaluate medicines upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access original data for studies that have been re-analysed, other types of GSK sponsored research, study documents without patient-level data and clinical studies not listed, please submit an enquiry <italic toggle="yes">via</italic> the website.</p>
              </fn>
              <fn fn-type="supplementary-material">
                <p>
This article has an editorial commentary: <ext-link xlink:href="https://doi.org/10.1183/13993003.02091-2022" ext-link-type="uri">https://doi.org/10.1183/13993003.02091-2022</ext-link></p>
              </fn>
              <fn>
                <p>Author contributions: GSK authors contributed to the conception, design and analysis of data. Study investigators contributed to the acquisition of data. All authors contributed to data interpretation or drafting or critically revising the article. All authors provided final approval and agreement of accountability.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>Conflict of interest: J. Patel, D. Bass, A. Cahn, K. Davy, S. Fernandes, A. Gupta, K. Hanrott, D. Inman, E. Jarvis, D. Lakshminarayanan, S. Mukherjee, C. O'Shea, L. Schifano, J.E. Smith, R. Williamson and M. Layton are shareholders and/or employees of GSK. A. Beishuizen, X. Bocca Ruiz, H. Boughanmi, H. Colombo, G.J. Criner, J. de-Miguel-Díez, P.A. Doreski, B. François, T. Hatlen, J.D. Isaacs, N. Kostina, T. Kropotina, J-C. Lacherade, P. Martinez-Ayala, C. McEvoy, F. Meziani, M. Monchi, R. Muñoz-Bermúdez, G. Plantefeve, L.E. Schwab, Z. Shahid, M. Shirano, E. Sprinz, C. Summers, N. Terzi and Y. Trefilova were investigators in the OSCAR trial, which was funded by GSK. X. Bocca Ruiz has served as a clinical trial investigator for AstraZeneca and Zambon. B. François reports consultancy fees with GSK, Enlivex, Inotrem, Takeda, Aridis, Transgene, AM-Pharma, Asahi-Kasai and Biomérieux within the past 36 months. R. Muñoz-Bermúdez has participated on an advisory board for GSK. J.D. Isaacs has received research funding from GSK, Janssen and Pfizer, and personal fees from AbbVie, BMS, Gilead, Roche and UCB, all outside the submitted work, as well as support for event attendance from Eli Lilly and Gilead. A. Beishuizen has received consultancy fees from GSK. C. McEvoy has received research funding from the National Institutes of Health, US Department of Defense, Patient-Centered Outcomes Research Institute, GSK and AstraZeneca. C. Summers’ institution has received research funding from GSK, AstraZeneca, the Wellcome Trust, The Medical Research Council and National Institute for Health Research to support her work outside the area of the submitted manuscript. C. Summers has received personal fees from AbbVie, Roche and GSK. G.J. Criner has received research grants from ALung Technologies Inc., American College of Radiology, American Lung Associations, AstraZeneca, BioScale Inc., Boehringer Ingelheim, BREATH Therapeutics Inc., COPD Foundation, Coridea/ZIDAN, Corvus, Dr Karen Burns of St Michael's Hospital, Fisher &amp; Paykel Healthcare Ltd, Galapagos NV, GSK, Kinevent, Lungpacer Medical Inc., National Heart Lung and Blood Institute, Nurvaira Inc., Patient-Centered Outcomes Research Institute, Pulmonary Fibrosis Foundation, PulmonX, Respironics Inc., Respivant Sciences, Spiration Inc., Steward St Elizabeth's Medical Center of Boston Inc. and Veracyte Inc.; and received personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, EOLO Medical, Gala Therapeutics, GSK, Helios Medical, Ion, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Respironics Inc., Respivant Sciences, The Implementation Group and Verona Pharma. J. Neisen is an employee and shareholder of AstraZeneca, and a shareholder and former employee of GSK. L.E. Schwab reports holding shares in Johnson &amp; Johnson and BMS, and participated on the Holy Cross Health Institutional Review Board. Z. Shahid has received research funding from Karyopharm. M. Shirano is an investigator in separate trials funded by Roche and AstraZeneca, and has received payment for lectures from Gilead Sciences. E. Sprinz participates on a data safety monitoring board/advisory board for, and has received consulting fees and honoraria from, GSK, Janssen and Gilead. M.A. Tidswell received a fee for serving on the independent data monitoring committee for this study, as well as for serving on a data safety monitoring board/advisory board for Spectral Diagnostics Inc., ReAlta Life Sciences Inc., Celltrion Inc., AstraZeneca and Molecular Partners AG. Additionally, M.A. Tidswell has held a research contract with Edesa Biotech Research Inc., RevImmune SAS, Spectral Diagnostics, Beyond Air Inc., National Institutes of Health and National Heart, Lung, and Blood Institute. D. Wyncoll received a fee for serving on the independent data monitoring committee for this study, has served as a study adjudicator for AstraZeneca, and reports consulting fees and/or honoraria from Gilead and Shionogi. J. de-Miguel-Díez, H. Boughanmi, J-C. Lacherade, P. Martinez-Ayala, T. Hatlen, G. Plantefeve, N. Terzi, M. Shirano, N. Kostina, T. Kropotina, Y. Trefilova and M. Monchi have no other conflicts of interest to declare.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p>Support statement: This study (GSK ID: 214094; NCT04376684) was funded by GSK. In 2013, GSK assumed exclusive worldwide responsibility of otilimab (previously MOR103) from MorphoSys AG for all development and commercialisation activities in all therapeutic fields. The study was supported in the UK by the National Institute for Health Research (NIHR) Comprehensive Research Network under the Urgent Public Health clinical trial scheme and the NIHR Newcastle Biomedical Research Centre in Ageing and Long-term Conditions. The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. Funding information for this article has been deposited with the <ext-link xlink:href="https://www.crossref.org/services/funder-registry/" ext-link-type="uri">Crossref Funder Registry</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="C1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rochwerg</surname><given-names>B</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>A</given-names></string-name>, <string-name><surname>Siemieniuk</surname><given-names>RA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A living WHO guideline on drugs for COVID-19</article-title>. <source>BMJ</source><year>2020</year>; <volume>370</volume>: <fpage>m3379</fpage>.<pub-id pub-id-type="pmid">32887691</pub-id></mixed-citation>
              </ref>
              <ref id="C2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schulte-Schrepping</surname><given-names>J</given-names></string-name>, <string-name><surname>Reusch</surname><given-names>N</given-names></string-name>, <string-name><surname>Paclik</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Severe COVID-19 is marked by a dysregulated myeloid cell compartment</article-title>. <source>Cell</source><year>2020</year>; <volume>182</volume>: <fpage>1419</fpage>–<lpage>1440</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.001</pub-id><pub-id pub-id-type="pmid">32810438</pub-id></mixed-citation>
              </ref>
              <ref id="C3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liao</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title>. <source>Nat Med</source><year>2020</year>; <volume>26</volume>: <fpage>842</fpage>–<lpage>844</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></mixed-citation>
              </ref>
              <ref id="C4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schurink</surname><given-names>B</given-names></string-name>, <string-name><surname>Roos</surname><given-names>E</given-names></string-name>, <string-name><surname>Radonic</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study</article-title>. <source>Lancet Microbe</source><year>2020</year>; <volume>1</volume>: <fpage>e290</fpage>–<lpage>e299</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-5247(20)30144-0</pub-id><pub-id pub-id-type="pmid">33015653</pub-id></mixed-citation>
              </ref>
              <ref id="C5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hazeldine</surname><given-names>J</given-names></string-name>, <string-name><surname>Lord</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Immunesenescence: a predisposing risk factor for the development of COVID-19?</article-title><source>Front Immunol</source><year>2020</year>; <volume>11</volume>: <fpage>573662</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.573662</pub-id><pub-id pub-id-type="pmid">33123152</pub-id></mixed-citation>
              </ref>
              <ref id="C6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pietrobon</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Teixeira</surname><given-names>FME</given-names></string-name>, <string-name><surname>Sato</surname><given-names>MN</given-names></string-name></person-group>. <article-title>Immunosenescence and inflammaging: risk factors of severe COVID-19 in older people</article-title>. <source>Front Immunol</source><year>2020</year>; <volume>11</volume>: <fpage>579220</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.579220</pub-id><pub-id pub-id-type="pmid">33193377</pub-id></mixed-citation>
              </ref>
              <ref id="C7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salje</surname><given-names>H</given-names></string-name>, <string-name><surname>Tran Kiem</surname><given-names>C</given-names></string-name>, <string-name><surname>Lefrancq</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Estimating the burden of SARS-CoV-2 in France</article-title>. <source>Science</source><year>2020</year>; <volume>369</volume>: <fpage>208</fpage>–<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abc3517</pub-id><pub-id pub-id-type="pmid">32404476</pub-id></mixed-citation>
              </ref>
              <ref id="C8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonanad</surname><given-names>C</given-names></string-name>, <string-name><surname>García-Blas</surname><given-names>S</given-names></string-name>, <string-name><surname>Tarazona-Santabalbina</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects</article-title>. <source>J Am Med Dir Assoc</source><year>2020</year>; <volume>21</volume>: <fpage>915</fpage>–<lpage>918</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2020.05.045</pub-id><pub-id pub-id-type="pmid">32674819</pub-id></mixed-citation>
              </ref>
              <ref id="C9">
                <label>9</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <comment>Risk for COVID-19 Infection, Hospitalization, and Death By Age Group</comment>. <ext-link xlink:href="www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html" ext-link-type="uri">www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html</ext-link><comment>Date last accessed: 26 November 2021</comment>.</mixed-citation>
              </ref>
              <ref id="C10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lang</surname><given-names>FM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>KMC</given-names></string-name>, <string-name><surname>Teijaro</surname><given-names>JR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches</article-title>. <source>Nat Rev Immunol</source><year>2020</year>; <volume>20</volume>: <fpage>507</fpage>–<lpage>514</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-0357-7</pub-id><pub-id pub-id-type="pmid">32576980</pub-id></mixed-citation>
              </ref>
              <ref id="C11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mehta</surname><given-names>P</given-names></string-name>, <string-name><surname>Porter</surname><given-names>JC</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities</article-title>. <source>Lancet Respir Med</source><year>2020</year>; <volume>8</volume>: <fpage>822</fpage>–<lpage>830</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30267-8</pub-id><pub-id pub-id-type="pmid">32559419</pub-id></mixed-citation>
              </ref>
              <ref id="C12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thwaites</surname><given-names>RS</given-names></string-name>, <string-name><surname>Sanchez Sevilla Uruchurtu</surname><given-names>A</given-names></string-name>, <string-name><surname>Siggins</surname><given-names>MK</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19</article-title>. <source>Sci Immunol</source><year>2021</year>; <volume>6</volume>: <fpage>eabg9873</fpage>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abg9873</pub-id><pub-id pub-id-type="pmid">33692097</pub-id></mixed-citation>
              </ref>
              <ref id="C13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fu</surname><given-names>B</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients</article-title>. <source>Nat Sci Rev</source><year>2020</year>; <volume>7</volume>: <fpage>nwaa041</fpage>. doi:<pub-id pub-id-type="doi">10.1093/nsr/nwaa041</pub-id></mixed-citation>
              </ref>
              <ref id="C14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kilian</surname><given-names>C</given-names></string-name>, <string-name><surname>Turner</surname><given-names>JE</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients</article-title>. <source>Sci Immunol</source><year>2021</year>; <volume>6</volume>: <fpage>eabf6692</fpage>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abf6692</pub-id><pub-id pub-id-type="pmid">33622974</pub-id></mixed-citation>
              </ref>
              <ref id="C15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hue</surname><given-names>S</given-names></string-name>, <string-name><surname>Beldi-Ferchiou</surname><given-names>A</given-names></string-name>, <string-name><surname>Bendib</surname><given-names>I</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 acute respiratory distress syndrome</article-title>. <source>Am J Respir Crit Care Med</source><year>2020</year>; <volume>202</volume>: <fpage>1509</fpage>–<lpage>1519</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.202005-1885OC</pub-id><pub-id pub-id-type="pmid">32866033</pub-id></mixed-citation>
              </ref>
              <ref id="C16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buckley</surname><given-names>CD</given-names></string-name>, <string-name><surname>Simón-Campos</surname><given-names>JA</given-names></string-name>, <string-name><surname>Zhdan</surname><given-names>V</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study</article-title>. <source>Lancet Rheumatol</source><year>2020</year>; <volume>2</volume>: <fpage>e677</fpage>–<lpage>e688</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2665-9913(20)30229-0</pub-id></mixed-citation>
              </ref>
              <ref id="C17">
                <label>17</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <comment>R&amp;D Blueprint: Novel Coronavirus COVID-19 Therapeutic Trial Synopsis</comment>. <ext-link xlink:href="www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf" ext-link-type="uri">www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf</ext-link>. <comment>Date last accessed: 9 August 2022</comment>.</mixed-citation>
              </ref>
              <ref id="C18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vincent</surname><given-names>JL</given-names></string-name>, <string-name><surname>Moreno</surname><given-names>R</given-names></string-name>, <string-name><surname>Takala</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</article-title>. <source>Intensive Care Med</source><year>1996</year>; <volume>22</volume>: <fpage>707</fpage>–<lpage>710</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01709751</pub-id><pub-id pub-id-type="pmid">8844239</pub-id></mixed-citation>
              </ref>
              <ref id="C19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mager</surname><given-names>DE</given-names></string-name>, <string-name><surname>Jusko</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>General pharmacokinetic model for drugs exhibiting target-mediated drug disposition</article-title>. <source>J Pharmacokinet Pharmacodyn</source><year>2001</year>; <volume>28</volume>: <fpage>507</fpage>–<lpage>532</lpage>. doi:<pub-id pub-id-type="doi">10.1023/A:1014414520282</pub-id><pub-id pub-id-type="pmid">11999290</pub-id></mixed-citation>
              </ref>
              <ref id="C20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asch</surname><given-names>DA</given-names></string-name>, <string-name><surname>Sheils</surname><given-names>NE</given-names></string-name>, <string-name><surname>Islam</surname><given-names>MN</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic</article-title>. <source>JAMA Intern Med</source><year>2021</year>; <volume>181</volume>: <fpage>471</fpage>–<lpage>478</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.8193</pub-id><pub-id pub-id-type="pmid">33351068</pub-id></mixed-citation>
              </ref>
              <ref id="C21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname><given-names>NG</given-names></string-name>, <string-name><surname>Jarvis</surname><given-names>CI</given-names></string-name>, <string-name><surname>van Zandvoort</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7</article-title>. <source>Nature</source><year>2021</year>; <volume>593</volume>: <fpage>270</fpage>–<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-03426-1</pub-id><pub-id pub-id-type="pmid">33723411</pub-id></mixed-citation>
              </ref>
              <ref id="C22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genovese</surname><given-names>MC</given-names></string-name>, <string-name><surname>Berkowitz</surname><given-names>M</given-names></string-name>, <string-name><surname>Conaghan</surname><given-names>PG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study</article-title>. <source>Lancet Rheumatol</source><year>2020</year>; <volume>2</volume>: <fpage>e666</fpage>–<lpage>e676</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2665-9913(20)30224-1</pub-id></mixed-citation>
              </ref>
              <ref id="C23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williamson</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Walker</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Bhaskaran</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title>. <source>Nature</source><year>2020</year>; <volume>584</volume>: <fpage>430</fpage>–<lpage>436</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmid">32640463</pub-id></mixed-citation>
              </ref>
              <ref id="C24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Recovery Collaborative Group</collab></person-group>. <article-title>Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</article-title>. <source>Lancet</source><year>2021</year>; <volume>397</volume>: <fpage>1637</fpage>–<lpage>1645</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00676-0</pub-id><pub-id pub-id-type="pmid">33933206</pub-id></mixed-citation>
              </ref>
              <ref id="C25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xiang</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage</article-title>. <source>J Transl Med</source><year>2020</year>; <volume>18</volume>: <fpage>206</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12967-020-02374-0</pub-id><pub-id pub-id-type="pmid">32434518</pub-id></mixed-citation>
              </ref>
              <ref id="C26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hazeldine</surname><given-names>J</given-names></string-name>, <string-name><surname>Lord</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Neutrophils and COVID-19: active participants and rational therapeutic targets</article-title>. <source>Front Immunol</source><year>2021</year>; <volume>12</volume>: <fpage>680134</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.680134</pub-id><pub-id pub-id-type="pmid">34149717</pub-id></mixed-citation>
              </ref>
              <ref id="C27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wicks</surname><given-names>IP</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>AW</given-names></string-name></person-group>. <article-title>Targeting GM-CSF in inflammatory diseases</article-title>. <source>Nat Rev Rheumatol</source><year>2016</year>; <volume>12</volume>: <fpage>37</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrrheum.2015.161</pub-id><pub-id pub-id-type="pmid">26633290</pub-id></mixed-citation>
              </ref>
              <ref id="C28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schultze</surname><given-names>JL</given-names></string-name>, <string-name><surname>Aschenbrenner</surname><given-names>AC</given-names></string-name></person-group>. <article-title>COVID-19 and the human innate immune system</article-title>. <source>Cell</source><year>2021</year>; <volume>184</volume>: <fpage>1671</fpage>–<lpage>1692</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.029</pub-id><pub-id pub-id-type="pmid">33743212</pub-id></mixed-citation>
              </ref>
              <ref id="C29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study</article-title>. <source>Lancet</source><year>2021</year>; <volume>397</volume>: <fpage>220</fpage>–<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32656-8</pub-id><pub-id pub-id-type="pmid">33428867</pub-id></mixed-citation>
              </ref>
              <ref id="C30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Temesgen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Burger</surname><given-names>CD</given-names></string-name>, <string-name><surname>Baker</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial</article-title>. <source>Lancet Respir Med</source><year>2021</year>; <volume>10</volume>: <fpage>237</fpage>–<lpage>246</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(21)00494-X</pub-id><pub-id pub-id-type="pmid">34863332</pub-id></mixed-citation>
              </ref>
              <ref id="C31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiang</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction</article-title>. <source>J Leukoc Biol</source><year>2022</year>; <volume>111</volume>: <fpage>261</fpage>–<lpage>267</lpage>. doi:<pub-id pub-id-type="doi">10.1002/JLB.3COVCRA0920-628RR</pub-id><pub-id pub-id-type="pmid">33759207</pub-id></mixed-citation>
              </ref>
              <ref id="C32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pupim</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TS</given-names></string-name>, <string-name><surname>Hudock</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>LB0001 mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation</article-title>. <source>Ann Rheum Dis</source><year>2021</year>; <volume>80</volume>: <fpage>198</fpage>–<lpage>199</lpage>. doi:<pub-id pub-id-type="doi">10.1136/annrheumdis-2021-eular.5012</pub-id></mixed-citation>
              </ref>
              <ref id="C33">
                <label>33</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Kiniksa Pharmaceuticals</collab></person-group>. <comment>Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-related ARDS</comment>. <year>2021</year>. <comment>https://investors.kiniksa.com/news-releases/news-release-details/kiniksaannounces-results-phase-3-trial-mavrilimumab-covid-19 Date last accessed: August 2022</comment>.</mixed-citation>
              </ref>
              <ref id="C34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fisher</surname><given-names>BA</given-names></string-name>, <string-name><surname>Veenith</surname><given-names>T</given-names></string-name>, <string-name><surname>Slade</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial</article-title>. <source>Lancet Respir Med</source><year>2021</year>; <volume>10</volume>: <fpage>255</fpage>–<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(21)00460-4</pub-id><pub-id pub-id-type="pmid">34922649</pub-id></mixed-citation>
              </ref>
              <ref id="C35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Temesgen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Burger</surname><given-names>C</given-names></string-name>, <string-name><surname>Baker</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>C-reactive protein as a biomarker for improved efficacy of lenzilumab in patients with COVID-19: results from the LIVE-AIR trial</article-title>. <source>Chest</source><year>2021</year>; <volume>160</volume>: <fpage>A2522</fpage>–<lpage>A2524</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2021.08.029</pub-id></mixed-citation>
              </ref>
              <ref id="C36">
                <label>36</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Humanigen Inc.</collab></person-group><comment>Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B</comment>. <year>2022</year>. <comment>https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Receives-Preliminary-Topline-Data-From-NIHNIAID-Study-of-Lenzilumab-in-ACTIV-5BET-B/default.aspx Date last accessed: August 2022.</comment></mixed-citation>
              </ref>
              <ref id="C37">
                <label>37</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Clinicaltrials.gov</collab></person-group>. <comment>Efficacy and Safety of GSK3196165 (Otilimab) <italic toggle="yes">Versus</italic> Placebo and Sarilumab in Participants with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)</comment>. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04134728" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04134728</ext-link><comment>Date last accessed: 16 February 2022</comment>.</mixed-citation>
              </ref>
              <ref id="C38">
                <label>38</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Clinicaltrials.gov</collab></person-group>. <comment>Efficacy and Safety of GSK3196165 <italic toggle="yes">Versus</italic> Placebo and Tofacitinib in Participants with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1) (NCT03980483)</comment>. <ext-link xlink:href="www.clinicaltrials.gov/ct2/show/NCT03980483" ext-link-type="uri">www.clinicaltrials.gov/ct2/show/NCT03980483</ext-link><comment>Date last accessed: 16 February 2022</comment>.</mixed-citation>
              </ref>
              <ref id="C39">
                <label>39</label>
                <mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>Clinicaltrials.gov</collab></person-group>. <comment>Efficacy and Safety of GSK3196165 <italic toggle="yes">Versus</italic> Placebo and Tofacitinib in Participants with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2) (NCT03970837)</comment>. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03970837" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03970837</ext-link><comment>Date last accessed: 16 February 2022</comment>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
